Lucence

03/17/2026

Dr Eric Topol’s latest analysis highlights the 1.8 Hazard Ratio for cardiovascular events associated with CHIP.

Lucence provided the deep sequencing assay for his test to detect the low-frequency signals that drive this risk. As the clinical perspective shifts toward "Important Potential," the next step is accessibility.

Read the full analysis here:

Ignoring a very informative lab test

03/09/2026

Everyone knows someone whose life has been disrupted by cancer. As cancer cases in Singapore rise, the conversation around early detection and prevention has never been more relevant.

Trustworthy, evidence-based information is what gives us peace of mind.

SGInnovate is leading by example as a proactive employer. By arranging Lucence screenings for their team, they are giving their people the clarity to understand their health and the power to act early.

Using liquid biopsy technology, a single blood draw screens for signals of up to 50 cancers and age-related diseases. This replaces the need for multiple, separate screenings for a more efficient and cost-effective path to early detection.

Proactive health starts with a conversation and support. Visit https://www.lucence.com/ to find out about proactive screenings for yourself or your team.

* LucenceINSIGHT™ is a screening test that is used in consultation with a healthcare professional.

03/06/2026

We are pleased to announce the appointment of Dr. Jonathan Poh as Chief Operating Officer at Lucence.

With a PhD in Cellular and Molecular Physiology and over a decade of oncology research experience, Jonathan’s journey with Lucence has been defined by his technical leadership. His pivotal role in developing our proprietary amplicon-based mirror barcoding sequencing chemistry has been essential to achieving the ultra-sensitivity our platform delivers today.

Jonathan leads the charge in scaling Lucence’s global operational footprint. He is responsible for the seamless integration of our clinical laboratory services and the expansion of our diagnostic reach, ensuring our operational scale matches the precision of our technology.

The path to transforming precision care for cancer and ageing-related diseases requires a relentless commitment to molecular depth. Under Jonathan’s leadership, we continue our mission to provide the clarity needed to identify risks early and manage health accurately.

03/05/2026

We are glad to share that Lucence and Partners Pathology have entered into a commercial partnership to expand access to advanced cancer diagnostics in Malaysia.

By combining ultra-sensitive molecular testing with local histopathology services, we are providing clinicians and patients with faster genomic insights to provide enhanced cancer detection and treatment selection. This collaboration also supports Penang’s role as a medical hub for world-class precision medicine and regional medical tourism.

Why this matters:

✅ Enhanced Accessibility: Making advanced genomic cancer testing more readily available in Malaysia ensures healthcare providers can access comprehensive profiling tools like LiquidHALLMARK®.

🔎 Actionable Insights: High-sensitivity testing enables the detection of clinically actionable biomarkers to better guide patient care.

Looking forward to bring the next generation of cancer care to more communities.

Find out more - https://www.lucence.com/news-updates/lucence-and-partners-pathology-collaborate-to-advance-cancer-diagnostics-in-malaysia

03/03/2026

Yesterday, we officially launched UNITED 2.0, a S$6 million project with the National Cancer Centre Singapore and Agency for Science, Technology and Research (A*STAR)'s DxD Hub, to advance the future of cancer diagnostics. This builds on UNITED 1.0 tissue testing, which has helped thousands of cancer patients across the region choose better treatments.

With national advancement into Whole Genome Sequencing (WGS) platform, we are helping patients achieve better and longer lives after diagnosis.

We want our innovations to prioritize the people who need them most. That's why we signed a landmark MOU with the Brain tumour Society of Singapore and DxD Hub - Diagnostics Development Hub. This partnership addresses this gap where patients and their families previously had little say in having the best diagnostic tools available to them.

As BTSS President, Melissa Lim, shared during the launch, a precise diagnosis is the foundation of a cancer patient's journey, but the process is often "hidden" from the patient. This MOU is our formal commitment to keeping the patient’s perspective at the heart of our research.

02/04/2026

We're glad to share that over 113 million people in the U.S now have access to LiquidHALLMARK® [1].

Since October 2024’s Medicare coverage for our ctRNA testing, access has grown to include both commercial and public health plans. Combining ctDNA and ctRNA testing in LiquidHALLMARK® means that more cancer patients will receive appropriate treatment options through better identification of targetable mutations [2].

Beyond this milestone, we remain committed to improving cancer detection and insights through expanded access so that patients can receive the best care possible.

More payer information is available at www.lucence.com

[1] Data on file.
[2] Samol J, et al. JCO Precis Oncol. 2025;9:e2500181.

01/28/2026

Imagine going to your neighborhood polyclinic for a simple blood test that shows you how your body is ageing. 🩺🩸

Our founder, Dr Tan Min-Han, spoke with The Straits Times about how precision healthcare is making this future a near-term reality. By identifying early cellular signals and mutations, we can move beyond a "one size fits all" approach to health.

This personalized data allows you to:
✅ Receive health guidance tailored to your specific DNA and biomarkers.
✅ Detect early signals in the blood that correlate with risks for heart attacks or strokes.
✅ Access critical health insights through simple blood tests instead of invasive procedures.

At Lucence, we believe that knowing exactly where you stand with your health is key. This clarity allows you to make small daily changes for a longer and healthier life. Simple adjustments to sleep or diet can make a significant impact.

Read the full "CEO Insights" feature here:

Dr Tan Min-Han said the company is well-placed to play a bigger role in educating people about their health as they age Read more at straitstimes.com. Read more at straitstimes.com.

12/19/2025

Dr. Gilberto Lopes, Chief of the Division of Medical Oncology and Associate Director of the Sylvester Comprehensive Cancer Center at the University of Miami, explores the evolving landscape of targeted therapy and how liquid biopsy — combining ctDNA and ctRNA analysis — supports personalized treatment planning.

Watch the full video here: https://www.lucence.com/patient-stories/dr.-gilberto-lopes

LiquidHALLMARK® by Lucence is an ultra-sensitive liquid biopsy test that analyzes ctDNA and ctRNA to enable tailored treatment decisions. Speak to your healthcare provider to seek advice on your options.

05/29/2025

Excited that our ctRNA and ctDNA liquid biopsy study has been selected as a Top 10 lung cancer study at by OncoAlert

Join the oral presentation at 8:00–9:30 AM CDT on June 2, 2025 https://lnkd.in/ghbWfKNM

The Abstracts in 🫁
These are some of our picks of TOP abstracts we look forward to be presented at the upcoming ASCO Meeting in Chicago 🇺🇸

⭐ Abs 8506: HERTHENA-LUNG02: PATRITUMAB DERUXTECAN IN RESISTANT EGFR-MUTATED ADVANCED NON-SMALL CELL LUNG CANCER AFTER A THIRD-GENERATION EGFR TKI

⭐Abs 8006: IMFORTE: LURBINECTEDIN + ATEZOLIZUMAB AS FIRST-LINE (1L) MAINTENANCE TREATMENT IN EXTENSIVE-STAGE SMALL CELL LUNG CANCER

⭐Abs 8512:TELISOTUZUMAB ADIZUTECAN (ABBV-400; TEMAB-A), A C-MET PROTEIN-TARGETING ADC, IN ADVANCED EGFR-MUTATED NON-SQUAMOUS (NSQ)

⭐LBA 8000: OVERALL SURVIVAL WITH NEOADJUVANT NIVOLUMAB (NIVO) + CHEMOTHERAPY (CHEMO) IN PATIENTS WITH RESECTABLE NSCLC IN CHECKMATE 816.

⭐LBA 8008: TARLATAMABVERSUS CHEMOTHERAPY AS SECOND-LINE (2L) TREATMENT FOR SMALL CELL LUNG CANCER (SCLC): PRIMARY ANALYSIS OF PH3 DELLPHI-304

⭐Abs 8001: NEOADJUVANT OSIMERTINIB ≤ CHEMOTHERAPY VS CT ALONE IN RESECTABLE EPIDERMAL GROWTH FACTOR RECEPTOR-MUTATED (EGFRM) NSCLC: NEOADAURA

⭐Abs 8015: ALECTINIB AS NEOADJUVANT TREATMENT IN POTENTIALLY RESECTABLE STAGE III ALK-POSITIVE NSCLC: FINAL ANALYSIS OF ALNEO

⭐Abs 8009: AEGEAN: ASSOCIATION OF POST-SURGICAL MRD STATUS W/ NEOADJUVANT CTDNA DYNAMICS, GENOMIC MUTATIONS / CLINICAL OUTCOMES IN RESECTABLE NSCLC

⭐Abs 8501: TROPION-LUNGO2: DATOPOTAMAB DERUXTECAN PLUS PEMBROLIZUMAB WITH OR WITHOUT PLATINUM CHEMOTHERAPY AS 1L FOR ADVANCED NSCLC

⭐Abs 8016: EFFICACY AND SAFETY OF NIVOLUMAB PLUS IPILIMUMAB FOR PRE-TREATED TYPE B3 THYMOMA AND THYMIC CARCINOMA: RESULTS FROM THE EORTC-ETOP NIVOTHYM

⭐Abs 3016: CLINICAL UTILITY OF CIRCULATING TUMOR RNA IN A COMBINED CIRCULATING TUMOR DNA & CTRNA NEXT-GENERATION SEQUENCING PAN-CANCER LIQUID BIOPSY ASSAY

Leads:
Senior Faculty:

05/23/2025

Join Lucence at as we present new data on our combined ctDNA and ctRNA liquid biopsy assay for cancer detection and monitoring!

🧬 Rapid Oral Presentation
Abstract #3016
Title: Clinical utility of circulating tumor RNA (ctRNA) in a combined circulating tumor DNA (ctDNA) and ctRNA next-generation sequencing (NGS) pan-cancer liquid biopsy assay
https://lnkd.in/ghbWfKNM
Presenter: Dr Daniel Chan
When: June 2, 8:00–9:30 AM CDT
Session: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

📌 Poster Presentation
Abstract #3062
Title: Clinical outcomes of a prospective multicenter study evaluating a combined circulating tumor DNA (ctDNA) and RNA (ctRNA) liquid biopsy assay in metastatic non-small cell lung cancer (NSCLC)
https://lnkd.in/gDhiWGc9
Presenter: Prof GILBERTO de lima LOPES Junior
When: June 2, 1:30–4:30 PM CDT (Poster Board #377)
Session: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Contact us at [email protected] to meet or for collaboration!

02/26/2025

Cancer is a global challenge, with close to 1 million deaths reported in India annually.

We’re glad to announce a collaboration with Agilus Diagnostics to contribute to India's cancer care.

For the first time, Indian cancer patients and physicians can now access LiquidHALLMARK® ctDNA and ctRNA to better personalize cancer treatment.

LiquidHALLMARK® is the only such test fully covered by US Medicare.

Together, we can do better!

Learn more: https://lnkd.in/d-YwBp5C